| |
 |
|
|
 |
|
 |
Proteomic analysis of stage Ⅰ primary lung adenocarcinoma aimed at individualisation of postoperative therapy
J. Maeda,A. Ogiwara,S. Akimoto,Y. Fukui,T. Oka,H. Kato etal
British J.Cancer, 1-8(2008) |
|
|
Personalized Medicine and Proteomics : Lessons from non-small cell Lung
Cancer
G. Marko-Varga, A. ogiwara, K. Nishio, H. Kato, Tim Higenbottam, etal
J.Proteome Research, 6, 2925-2935 (2007) |
|
|
Frequent loss of E-cadherin and/or catenins in intrabronchial lesions during carcinogenesis of the bronchial epithelium
Y. Kato, T. Hirano, K. Yoshida, K. Yashima, S. Akimoto, K. Tsuji, T. Ohira, M. Tsuboi, N. Ikeda, Y. Ebihara and H. Kato
Lung Cancer, 48, 323-330 (2005) |
|
|
Clinical-scale high-throughput human plasma proteome analysis: Lung adenocarcinoma
K. Fujii, T. Nakano, M. Kanazawa, S. Akimoto, T. Hirano, H. Kato, and T. Nishimura
Proteomics, 5, 1150-1159 (2005) |
|
|
Protein identification from product ion spectra of peptides validated by
correlation between measured and predicted elution times in liquid chromatography/mass
spectrometry
T. Kawakami, K. Tateishi, Y. Tamano, T. Ishikawa, K. Kuroki, and T. Nishimura
Proteomics, 5, 856-864 (2005) |
|
|
|
